07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Active Biotech, NeoTX Therapeutics deal

Active granted NeoTX exclusive, worldwide rights to develop and commercialize Anyara naptumomab estafenatox for cancer. Active will receive a $250,000 upfront payment and is eligible for development, regulatory and commercialization milestones, plus double-digit royalties. Active...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Anyara naptumomab estafenatox: Additional Phase II/III data

In a subgroup analysis of the 25% of patients with low or normal levels of baseline IL-6 and expected anti-superantigen antibody levels, Anyara plus IFN alpha led to a median OS of 63.3 months vs....
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Anyara naptumomab estafenatox: Phase II/III data

Top-line data from a European Phase II/III trial in 513 patients with advanced RCC showed that Anyara plus interferon (IFN) alpha missed the primary endpoint of improving OS vs. IFN alpha alone. Active Biotech said...
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) was up DKK26 to DKK441 on Friday after Merck & Co. Inc. (NYSE:MRK) said it submitted a BLA to FDA in January for its Grass Allergy Immunotherapy Tablet. Merck has...
01:28 , Jan 29, 2013 |  BC Extra  |  Clinical News

Active Biotech's Anyara misses RCC endpoint

Active Biotech AB (SSE:ACTI) fell SEK7.50 (13%) to SEK51.50 on Monday after it said Anyara naptumomab estafenatox plus interferon (IFN) alpha missed the primary endpoint of improving overall survival (OS) vs. IFN alone in a...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest...